Migraine

migraine

← back to Neurology

Summary

Updated AHS consensus on integrating newer acute and preventive migraine therapies into adult practice, building on the prior position statement without altering established treatment principles. New acute options covered include gepants (ubrogepant, rimegepant), the ditan lasmiditan, celecoxib oral solution, and remote electrical neuromodulation (REN); new preventive options include IV eptinezumab, with emerging dual-use gepants (rimegepant, atogepant). Recommendations specify when to escalate from triptans/established preventives to these newer agents and how to measure response.

Current guideline: AHS 2021 Migraine Consensus · download Anki sub-deck

Versions

Table of contents